Neuroscience

World Parkinson's Day
#Charity #Funding #Neurodegenerative disorders #Neuroscience #Parkinson's

Parkinson’s researchers receive nearly $3 million in grant funding

The US Parkinson’s Foundation has invested nearly $3 million for 33 grants to accelerate Parkinson’s disease (PD) research. The research grants will fund scientists conducting studies across various aspects of PD to bring forward new therapies, treatments, and ultimately a cure for the disease. Read More

#News

Lecanemab
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #UK

UK regulator rules benefits of lecanemab do not justify the cost

The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. This was the decision by the National Institute for Health and Care Excellence (NICE) in draft guidance on the drug. Lecanemab is for slowing… Read More

#News #Regulatory #Trending News

#Career #Interview #Meet the Researcher #Neurodegenerative disorders

Meet the researcher: Dr Joanne Taylor

DDW’s Megan Thomas looks at a day in the life of Dr Joanne Taylor, Senior Vice President and Head of Discovery Research at Gain Therapeutics. MT: Can you provide a top line summary of your research?  JT: We are developing novel small molecule, disease-modifying, allosteric regulators to treat serious diseases… Read More

#Exclusive Content

Brain inflammation
#Cell culture #Drug discovery #High throughput screening #In vitro #Neuroscience

Balancing in vitro models of neuroinflammation

Dr Gareth Edwards, Senior Bioassay Scientist at Cellomatics Biosciences, explores how modern techniques and high-throughput screening can enhance workflows in neuroinflammation.  Inflammation occurs when specific stimuli induce phenotypic changes by activating signalling cascades that amplify downstream responses. It plays vital roles in both disease progression and tissue repair; in other words,… Read More

#Exclusive Content

Former soldier suffering from PTSD
#FDA #MDMA #Psychiatry #PTSD

FDA urged to approve MDMA-assisted therapy for PTSD

Two veteran advocacy organisations, Reason for Hope and the Veteran Mental Health Leadership Coalition, have issued a joint statement urging the US Food and Drug Administration (FDA) to approve MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Last month, an FDA Advisory Committee recommended against approval, with only two out of… Read More

#News #Regulatory

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights vodcast: 7 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   GLP-1 receptor agonists have dominated… Read More

#News

#Antidepressants #Neurology #Neuropsychiatric disorders #Neuroscience #Psychedelics #Psychiatry

Reshaping neuropsychiatry

Dr Anantha Shekhar, MD PhD, Dean of the University of Pittsburgh School of Medicine, explores synapse structure and function in neuroscience and how neuroplasticity can present new opportunities for drug development. With contributions from Rob Houghtaling, MS and John Donello, PhD, Gate Neurosciences. In March 2019, the US FDA approved… Read More

#Exclusive Content

Neurons in the brain
#Centogene #Drug targets #Genetics #Neuroscience #Parkinson's

15% of Parkinson’s cases linked to genetic factors, study says 

Centogene has announced data from its Rostock International Parkinson’s Disease (ROPAD) Study revealing the genetic factors and prevalence of Parkinson’s disease (PD).   The findings from the study indicate that approximately 15% of PD-related cases are tied to genetic variants, with the majority being linked to LRRK2 and… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights podcast: 5 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

This week in drug discovery (29 July – 2 August) 

News round-up for 29 July – 2 August by DDW Senior Digital Content Editor Diana Spencer. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide. The top stories:… Read More

#News

CT scans of the brain
#Alzheimer's #Antibodies #Biogen #Biologics #Eisai #Neurodegenerative disorders

Data demonstrate long-term effect of lecanemab in early Alzheimer’s

Lecanemab-irmb (Leqembi), an anti-amyloid beta (Aβ) protofibril antibody, continues to show benefit for early Alzheimer’s disease (AD) patients over three years, according to new trial results. Eisai and Biogen shared the latest findings at the Alzheimer’s Association International Conference (AAIC) 2024, held in Philadelphia. Read More

#News

#Alpha Cognition #Alzheimer's #Drug delivery #FDA #Neurodegenerative disorders

US regulator approves galantamine prodrug for Alzheimer’s

The US Food and Drug Administration (FDA) has granted approval for Alpha Cognition’s Zunveyl (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease (AD). Tolerability affects therapy adherence, with data showing that 55% of AD patients discontinue their medication after one year, mainly due to GI side… Read More

#News #Regulatory

Toxoplasma gondii
#Neurodegenerative disorders #Neurology #Parasitic disease #Tel Aviv University #University of Glasgow

Engineered brain parasites could treat cognitive disorders

Researchers have discovered a way of using engineered brain parasites to deliver treatments for neurological conditions across the blood-brain-barrier. The study – led by the University of Glasgow in collaboration with Tel Aviv University and an international team of researchers – represents an exciting new field… Read More

#Editor's Choice #News

Jigsaw puzzle of the brain
#Alzheimer's #Dementia #Diabetes #GLP-1 #Novo Nordisk #Phase II trial #Weight loss

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language… Read More

#News #Trending News

#Brain disease #Johnson & Johnson #Neurology #Neuroscience

Shaping the future of neuroscience

Berkin Gökbudak, Senior Director of Commercial Strategy for Neuroscience, Pulmonary Hypertension & Cardiovascular & Metabolism, at Johnson & Johnson, looks towards neuroscience strategies that can help advance treatments for brain disorders. The human brain is the last, and greatest, scientific frontier – it’s been described as the most complex structure… Read More

#Exclusive Content

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

New DDW Highlights podcast: 29 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy,… Read More

#News